Purpose This review provides an update on the current clinical, epidemiological and
pathophysiological evidence alongside the diagnostic, prevention and treatment approach …

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side
effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically …

Chemotherapy-induced neuropathy is a common, dose-dependent adverse effect of several
antineoplastics. It can lead to detrimental dose reductions and discontinuation of treatment …

With a 3‐fold increase in the number of cancer survivors noted since the 1970s, there are
now over 28 million cancer survivors worldwide. Accordingly, there is a heightened …

The peripheral nervous system can be vulnerable to the toxic action of several drugs since it
is not protected as effectively as the central nervous system from noxious exogenous agents …

Peripheral polyneuropathy is a common and dose-limiting side effect of many important
chemotherapeutic agents. Most such neuropathies are characterized by early axonal …

Chemotherapy induced peripheral neuropathy (CIPN) is a type of neuropathic pain that is a
major dose-limiting side-effect of potentially curative cancer chemotherapy treatment …

Animal models are pivotal for understanding the mechanism of neuropathic pain and
development of effective therapy for its optimal management. A battery of neuropathic pain …

Paclitaxel chemotherapy frequently induces neuropathic pain during and often persisting
after therapy. The mechanisms responsible for this pain are unknown. Using a rat model of …

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a common, potentially severe and
dose-limiting adverse effect of cancer treatment; however, the effects of CIPN on the daily life …